top news stories diabetes, diabetes, University of Arizona, type 2, heart disease, study, $1.1 million,

Top Diabetes News of Today

BY ADIN TARR: The University of Arizona received a $1.1 million grant to study the biology underlying the connection between type 2 diabetes and cardiovascular disease.

The UA’s Dr. Yann Klimentidis said an end goal for this type of research is to learn more about individuals.

“So, being able to say based on your genetic profile, based on your DNA sequence looks like you are at very high risk at heart disease or based on your genetic profile you are at high risk of developing Type 2 diabetes if you take statins,” said Dr. Klimentidis as a way of understanding why this happens to improve outcomes for patients.

The study will utilize publicly available health and genetic information from databases across the world, covering at least 650,000 people. The research could also produce knowledge to help prescribe drugs based on a person’s genetics. (read more)


Diabetes ‘technological wave’ has too much upside to ignore: JP Morgan

BY ERIN BLACK: New technologies for diabetes treatment are becoming essential for those who suffer from the disease, according to J.P. Morgan, and that could make companies such as Dexcom compelling investment opportunities.

“The diabetes space is currently experiencing its biggest technological wave of innovation from glucose measurement (continuous glucose monitoring) to insulin dosing (insulin pumps),” analyst Robbie Marcus said in a note to clients Friday. “CGM is becoming an essential tool for patients and is now at the level of sensitivity that it is eliminating the need for fingersticks with blood glucose monitoring.” (read more)

New hope from the ‘seven year switch’ in Type 1 diabetes

BY SCIENCE DAILY: New research has shown that the rapid decline in insulin production that causes type 1 diabetes continues to fall over seven years and then stabilizes.

A team at the University of Exeter Medical School found evidence that the amount of insulin produced declines by almost 50% each year for seven years. At that point, the insulin levels stabilize.

The finding is a major step forward in understanding Type 1 diabetes and contradicts previous beliefs that the insulin produced by people with the condition drops relentlessly with time. It offers the hope that by understanding what changes after seven years, new strategies could be developed to preserve insulin secreting beta-cells in patients. (read more)


Dr. Wood: Take steps to limit your risk for Type 2 diabetes

BY DR. RACHEL WOOD: Though there are different kinds of diabetes, type 2 is the most common. According to the Center for Disease Control and Prevention, roughly 1 out of 3 American adults have prediabetes. For those 84 million Americans, “without intervention, many people with prediabetes could develop type 2 diabetes within 5 years.”

For some, this chronic disease can be prevented by understanding what changes to make in daily living behaviors, and by understanding the symptoms.

Type 2 diabetes is a condition in which sugar (glucose) builds up in a person’s blood. In a healthy body, insulin (a hormone) helps move glucose from your blood into your cells where your body can use it for energy. When someone has diabetes, they can’t use insulin effectively, so your body relies on other energy sources in your tissue, muscle or organs. (read more)

Researchers change clinical practice for infants with diabetes

BY MEDICAL XPRESS: It is not necessary to treat diabetic infants with insulin syringes. This will be new clinical practice after a recent study, now published in Lancet Diabetes & Endocrinology in which researchers from Bergen and Exeter tested the replacement of insulin syringes with tablets.

“All infants diagnosed with diabetes before six to seven months of age should be given a rapid gene test to change treatment as soon as possible from insulin to sulfonylurea tablets. They can expect a long and very good effect of the treatment of blood sugar control, and the treatment is safe,” says Professor Pål Rasmus Njølstad at the University of Bergen. (read more)